The combination of an SGLT2 inhibitor and insulin was associated with improved glycemic control; however, the risk of diabetic ketoacidosis and genital tract infection from the SGLT2 inhibitor was particularly increased in patients receiving insulin, which suggests that the role of an SGLT2 inhibitor as an add‐on therapy to insulin will be limited.33, 34. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.